Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses

Alexander D. Sherry, Adina H. Passy, Zachary R. McCaw, Joseph Abi Jaoude, Timothy A. Lin, Ramez Kouzy, Avital M. Miller, Gabrielle S. Kupferman, Esther J. Beck, Pavlos Msaouel

Type: Article

Publication Date: 2024-08-30

Citations: 3

DOI: https://doi.org/10.1200/cci.24.00102

View Publication

Locations

JCO Clinical Cancer Informatics - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Statistical analysis of clinical trial data in cancer research	2024	Hui Sun
+	MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in Oncology? Insights From a Cross-Tumor Case Study	2022	Oğuzhan Alagöz S Srinivasan I Kim Murat Kurt
+ PDF Chat	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2019	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfé Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+ PDF Chat	Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials	2023	Timothy A. Lin Alexander D. Sherry Ethan B. Ludmir
+	Definitions and statistical properties of master protocols for personalized medicine in oncology	2017	Lindsay A. Renfro Sumithra J. Mandrekar
+ PDF Chat	More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study	2022	Raphaëlle Momal Paul Trichelair Michaël G. B. Blum Félix Balazard
+	Novel Use of Patient-Specific Covariates From Oncology Studies in the Era of Biomedical Data Science: A Review of Latest Methodologies	2022	Ronghui Xu Guanhua Chen Michael Connor James D. Murphy
+	Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2023	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfè Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+	Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2023	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfè Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+	Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Table S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?	2022	Suji Udayakumar Sasha Thomson Albiruni R. Abdul Razak Kelvin Chan
+ PDF Chat	The Importance of Identifying and Validating Prognostic Factors in Oncology	2010	Susan Halabi Kouros Owzar
+	Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: prognostic scores as a way forward	2024	Luca Locher Miquel Serra‐Burriel Dario Trapani Emanuel Nussli Kerstin Noëlle Vokinger
+ PDF Chat	Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes	2019	Hajime Uno Miki Horiguchi Michael J. Hassett
+	Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.	2018	Rifaquat Rahman Geoffrey Fell Lorenzo Trippa Brian M. Alexander
+	Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions	2024	Jian Wang Binbing Yu Yannan N. Dou Jacques Mascaro
+ PDF Chat	Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement	2021	Changyu Shen Enrico G. Ferro Huiping Xu Daniel B. Kramer Rushad Patell Dhruv S. Kazi
+	PCN63 META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER	2007	Rebecca A. Miksad Vera Zietemann R Gothe Ralf Schwarzer Annette Conrads‐Frank P Schnell-lnderst Björn Stollenwerk P Plieschnegger Emilio Esteban Uwe Siebert
+	Risk Model Development and Validation in Clinical Oncology: Lessons Learned	2022	Gary H. Lyman Pavlos Msaouel Nicole M. Kuderer

Works That Cite This (2)

Action	Title	Year	Authors
+	Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Zachary R. McCaw Ethan B. Ludmir Erik W. van Zwet
+	Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials	2025	Alexander D. Sherry Yufei Liu Pavlos Msaouel Timothy A. Lin Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam

Works Cited by This (41)

Action	Title	Year	Authors
+	Understanding controlled trials: Baseline imbalance in randomised controlled trials	1999	Chris Roberts David Torgerson
+	The Hazards of Hazard Ratios	2009	Miguel A. Hernán
+ PDF Chat	Confounding and Collapsibility in Causal Inference	1999	Sander Greenland Judea Pearl James M. Robins
+ PDF Chat	Optimism bias leads to inconclusive results—an empirical study	2010	Benjamin Djulbegović Ambuj Kumar Anja Magazin Anneke T. Schroen Heloisa P. Soares Iztok Hozo Mike Clarke Daniel J. Sargent Michael J. Schell
+	Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems	2002	Stuart J. Pocock Susan E. Assmann Laura E. Enos Linda Kasten
+	Covariate imbalance and random allocation in clinical trials	1989	Stephen Senn
+	Sample size calculations in randomised trials: mandatory and mystical	2005	Kenneth F. Schulz David A. Grimes
+	Testing for baseline balance in clinical trials	1994	Stephen Senn
+ PDF Chat	Evaluation of New Treatments in Radiation Oncology	2005	Heloisa P. Soares Ambuj Kumar Stephanie Daniels S. Swann Alan Cantor Iztok Hozo Mike Clark Fadila Serdarević Clement K. Gwede Andy Trotti
+ PDF Chat	The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients	2013	Daniel Westreich Sander Greenland